| P/E (FY) | — | Sales (TTM) | $3.2M |
| Earnings (TTM) | -$2.2M | ROE | −40.00% |
| Net Margin | −90.07% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 20.36% |
| Market Cap | $5.7M | Trading Days | 2523 |
| 52W High | 13.93 |
| 52W Low | 1.90 |
| % Off High | −82.05% |
| YTD | 15.21% | 1Y | −31.36% |
| 3Y | −33.51% | 5Y | −92.21% |
| 10Y | −99.54% | Since incept. (ann.) | −41.85% |
| Ann. Volatility (1Y) | 166.45% | Ann. Volatility (3Y) | 113.21% |
| Sharpe (1Y) | 0.32 | Sharpe (3Y) | 0.30 |
| Max Drawdown (1Y) | −80.50% | Max Drawdown (3Y) | −80.50% |
| Beta (3Y, vs SPY) | 1.18 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CVKD | Cadrenal Therapeutics, Inc. | $5.8M | — |
| CURX | Curanex Pharmaceuticals Inc | $5.6M | — |
| INM | InMed Pharmaceuticals Inc. | $5.5M | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $5.5M | — |
| ACXP | Acurx Pharmaceuticals, Inc. | $6.1M | — |
| LIANY | LianBio | $5.4M | — |
| SNGX | SOLIGENIX, INC. | $5.4M | — |
| GOVX | GeoVax Labs, Inc. | $5.4M | — |
| PULM | Pulmatrix, Inc. | $6.1M | — |
| APVO | Aptevo Therapeutics Inc. | $5.2M | — |
| ALZN | Alzamend Neuro, Inc. | $6.3M |
| — |
| ADIL | ADIAL PHARMACEUTICALS, INC. | $6.3M | — |
